Metastatic pancreatic cancer: ASCO guideline update

Davendra P.S. Sohal, Erin B. Kennedy, Pelin Cinar, Thierry Conroy, Mehmet S. Copur, Christopher H. Crane, Ignacio Garrido-Laguna, Michelle W. Lau, Tyler Johnson, Smitha Krishnamurthi, Cassadie Moravek, Eileen M. O'Reilly, Philip A. Philip, Shubham Pant, Manish A. Shah, Vaibhav Sahai, Hope E. Uronis, Neeha Zaidi, Daniel Laheru

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


PURPOSE The aim of this work was to provide an update to the ASCO guideline on metastatic pancreatic cancer pertaining to recommendations for therapy options after first-line treatment. METHODS ASCO convened an Expert Panel and conducted a systematic review to update guideline recommendations for second-line therapy for metastatic pancreatic cancer. RESULTS One randomized controlled trial of olaparib versus placebo, one report on phase I and II studies of larotrectinib, and one report on phase I and II studies of entrectinib met the inclusion criteria and inform the guideline update. RECOMMENDATIONS New or updated recommendations for germline and somatic testing for microsatellite instability high/mismatch repair deficiency, BRCA mutations, and TRK alterations are provided for all treatmenteligible patients to select patients for recommended therapies, including pembrolizumab, olaparib, larotrectinib, or entrectinib, or potential clinical trials. The Expert Panel continues to endorse the remaining recommendations for second-line chemotherapy, as well as other recommendations related to treatment, follow-up, and palliative care from the 2018 version of this guideline. Additional information is available at guidelines.

Original languageEnglish (US)
Pages (from-to)3217-3230
Number of pages14
JournalJournal of Clinical Oncology
Issue number27
StatePublished - Sep 20 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Metastatic pancreatic cancer: ASCO guideline update'. Together they form a unique fingerprint.

Cite this